@DocMcstuffins and @whytee
I think you need to get your act together and start reading from the same hymn book.
According to the Doc, the use of Temcell is saturated in Japan due to it being a small market. In other words, there can’t be any growth as it is being fully used already.
However, according to Whytee, if efficacy is as good as suggested, then why isn’t everyone using it who could?
A somewhat difference in views is it not? Seems to me you are arguing against each other. Now that would be a first, just like the FDA decision might be on Wednesday night.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-47
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.01 |
Change
-0.065(6.07%) |
Mkt cap ! $1.147B | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.05 | 99.5¢ | $9.449M | 9.298M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 64999 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.02 | 64541 | 3 |
View Market Depth
| Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |